Home
RPRX
RPRX News

Latest Royalty Pharma plc (RPRX) News on November 27, 2025

Vaximm and BCME link on oral cancer immunotherapy platform

Pharmaceutical Technology

3 days ago

Vaximm and BCME link on oral cancer immunotherapy platform

MT Newswires

6 days ago

Royalty Pharma Insider Sold Shares Worth $5,192,656, According to a Recent SEC Filing

MT Newswires

8 days ago

Royalty Pharma Insider Sold Shares Worth $2,735,329, According to a Recent SEC Filing

Royalty Pharma (RPRX): Is the Stock Undervalued After Higher 2025 Revenue Guidance and Major Buyback Completion?

Simply Wall St.

9 days ago

Royalty Pharma (RPRX): Is the Stock Undervalued After Higher 2025 Revenue Guidance and Major Buyback Completion?

How Analyst Views on Royalty Pharma Are Shifting

Simply Wall St.

9 days ago

How Analyst Views on Royalty Pharma Are Shifting

3 Value Stocks with Warning Signs

StockStory

9 days ago

3 Value Stocks with Warning Signs

3 Low-Volatility Stocks We Find Risky

StockStory

10 days ago

3 Low-Volatility Stocks We Find Risky

Eli Lilly Leads Three Stocks Near Buy Points

Investor's Business Daily

13 days ago

Eli Lilly Leads Three Stocks Near Buy Points

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

StockStory

14 days ago

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

15 days ago

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

Zacks

a month ago

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

2 Reasons to Avoid RPRX and 1 Stock to Buy Instead

StockStory

a month ago

2 Reasons to Avoid RPRX and 1 Stock to Buy Instead

What Do Analysts Think About Royalty Pharma Plc (RPRX)?

Insider Monkey

a month ago

What Do Analysts Think About Royalty Pharma Plc (RPRX)?

Balancing Innovation and Income: A2 Fund Shares 2026 Market Outlook Following 75% YTD Fund Growth

PR Newswire

a month ago

Balancing Innovation and Income: A2 Fund Shares 2026 Market Outlook Following 75% YTD Fund Growth

Royalty Pharma (RPRX) Valuation: Is There More Upside After This Year’s 40% Rally?

Simply Wall St.

a month ago

Royalty Pharma (RPRX) Valuation: Is There More Upside After This Year’s 40% Rally?

3 Healthcare Stocks We Keep Off Our Radar

StockStory

a month ago

3 Healthcare Stocks We Keep Off Our Radar

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

GlobeNewswire

2 months ago

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Insider Monkey

2 months ago

Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

GlobeNewswire

2 months ago

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

TD Cowen Maintains a Buy on Royalty Pharma (RPRX)

Insider Monkey

2 months ago

TD Cowen Maintains a Buy on Royalty Pharma (RPRX)

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

StockStory

2 months ago

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts

Insider Monkey

2 months ago

Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts

Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program

Insider Monkey

3 months ago

Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

GlobeNewswire

3 months ago

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

GlobeNewswire

3 months ago

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?

Simply Wall St.

3 months ago

Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?

Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase

Insider Monkey

3 months ago

Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase

Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal

Insider Monkey

3 months ago

Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal

Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

Insider Monkey

3 months ago

Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

Investors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past year

Simply Wall St.

5 months ago

Investors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past year

5 Revealing Analyst Questions From Royalty Pharma’s Q1 Earnings Call

StockStory

5 months ago

5 Revealing Analyst Questions From Royalty Pharma’s Q1 Earnings Call

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

GlobeNewswire

5 months ago

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

Morningstar Research

5 months ago

Analyst Report: Royalty Pharma plc

RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives

StockStory

6 months ago

RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire

6 months ago

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock?

Simply Wall St.

6 months ago

Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock?

Royalty Pharma Completes the Acquisition of Its External Manager

GlobeNewswire

6 months ago

Royalty Pharma Completes the Acquisition of Its External Manager

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

GlobeNewswire

6 months ago

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

Morningstar Research

7 months ago

Analyst Report: Royalty Pharma plc

Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates

StockStory

7 months ago

Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates

Royalty Pharma Reports First Quarter 2025 Results

GlobeNewswire

7 months ago

Royalty Pharma Reports First Quarter 2025 Results

Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

StockStory

7 months ago

Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

Royalty Pharma (NasdaqGS:RPRX) Declares US$0.22 Dividend for Q2 2025

Simply Wall St.

7 months ago

Royalty Pharma (NasdaqGS:RPRX) Declares US$0.22 Dividend for Q2 2025

Royalty Pharma Declares Second Quarter 2025 Dividend

GlobeNewswire

7 months ago

Royalty Pharma Declares Second Quarter 2025 Dividend

Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

GlobeNewswire

7 months ago

Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors

GlobeNewswire

8 months ago

Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors

Royalty Pharma Announces Upcoming Investor Day

GlobeNewswire

8 months ago

Royalty Pharma Announces Upcoming Investor Day

Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility?

Insider Monkey

8 months ago

Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility?

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

GlobeNewswire

9 months ago

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey

9 months ago

Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025

Morningstar Research

9 months ago

Analyst Report: Royalty Pharma plc

Morningstar Research

9 months ago

Analyst Report: Royalty Pharma plc

Royalty Pharma Announces R&D Funding Collaboration With Biogen

GlobeNewswire

9 months ago

Royalty Pharma Announces R&D Funding Collaboration With Biogen

GuruFocus.com

9 months ago

Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates

StockStory

10 months ago

Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates

Royalty Pharma Reports Q4 and Full Year 2024 Results

GlobeNewswire

10 months ago

Royalty Pharma Reports Q4 and Full Year 2024 Results

Royalty Pharma Earnings: What To Look For From RPRX

StockStory

10 months ago

Royalty Pharma Earnings: What To Look For From RPRX

Is Now The Time To Put Royalty Pharma (NASDAQ:RPRX) On Your Watchlist?

Simply Wall St.

10 months ago

Is Now The Time To Put Royalty Pharma (NASDAQ:RPRX) On Your Watchlist?

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

GlobeNewswire

10 months ago

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

GlobeNewswire

10 months ago

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?

Insider Monkey

10 months ago

Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?

Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now

Insider Monkey

10 months ago

Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now

Royalty Pharma (NASDAQ:RPRX) Has Announced That It Will Be Increasing Its Dividend To $0.22

Simply Wall St.

10 months ago

Royalty Pharma (NASDAQ:RPRX) Has Announced That It Will Be Increasing Its Dividend To $0.22

Here’s Why Royalty Pharma plc (RPRX) Led This Week’s Rally

Insider Monkey

10 months ago

Here’s Why Royalty Pharma plc (RPRX) Led This Week’s Rally

Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?

Insider Monkey

a year ago

Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

GlobeNewswire

a year ago

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma Announces Dividend Increase

GlobeNewswire

a year ago

Royalty Pharma Announces Dividend Increase

Jim Cramer on Royalty Pharma plc (RPRX): ‘Disappointing Stock, Man, I Can’t Believe It’

Insider Monkey

a year ago

Jim Cramer on Royalty Pharma plc (RPRX): ‘Disappointing Stock, Man, I Can’t Believe It’

Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the company

Simply Wall St.

a year ago

Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the company

Jim Cramer Calls Royalty Pharma (RPRX) ‘Disappointing’ But Recommends Holding – ‘I Want You To Stick With It’

Insider Monkey

a year ago

Jim Cramer Calls Royalty Pharma (RPRX) ‘Disappointing’ But Recommends Holding – ‘I Want You To Stick With It’

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Royalty Pharma to Present at Upcoming Investor Conferences

Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?

Insider Monkey

a year ago

Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

GlobeNewswire

a year ago

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues

Simply Wall St.

a year ago

Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

GlobeNewswire

a year ago

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

GuruFocus.com

a year ago

Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions

Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

GuruFocus.com

a year ago

Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

Morningstar Research

a year ago

Analyst Report: Royalty Pharma plc

Royalty Pharma Reports Third Quarter 2024 Results

GlobeNewswire

a year ago

Royalty Pharma Reports Third Quarter 2024 Results

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo

GlobeNewswire

a year ago

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

PR Newswire

a year ago

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire

a year ago

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21

Simply Wall St.

a year ago

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21

Royalty Pharma Declares Fourth Quarter 2024 Dividend

GlobeNewswire

a year ago

Royalty Pharma Declares Fourth Quarter 2024 Dividend

GuruFocus.com

a year ago

Royalty Pharma PLC (RPRX) Q2 2024 Earnings Call Highlights: Surpassing Growth Expectations and ...

Royalty Pharma plc (RPRX): Among The Stocks With Biggest Upside Potential According to Hedge Funds

Insider Monkey

a year ago

Royalty Pharma plc (RPRX): Among The Stocks With Biggest Upside Potential According to Hedge Funds

Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Simply Wall St.

a year ago

Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

GlobeNewswire

a year ago

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

GlobeNewswire

a year ago

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference

GlobeNewswire

a year ago

Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference

Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’

Insider Monkey

a year ago

Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’

Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now?

Insider Monkey

a year ago

Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now?

Royalty Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Royalty Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

GuruFocus.com

a year ago

Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

Morningstar Research

a year ago

Analyst Report: Royalty Pharma plc

Royalty Pharma Reports Second Quarter 2024 Results

GlobeNewswire

a year ago

Royalty Pharma Reports Second Quarter 2024 Results

Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

GlobeNewswire

a year ago

Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Share on Social Networks: